[Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor].
Dual antiplatelet therapy with clopidogrel combined to aspirin reduces ischemic events in a wide range of patients with cardiovascular disease. However, a large interindividual variability has been observed in the pharmacodynamics response of clopidogrel with lower platelet inhibition associated with increased risk for major adverse cardiovascular events. Multiple mechanisms have been proposed for the variable response to clopidogrel, among which the impact of pharmacogenetic seems to play an important role. This article reviews the role of genetic polymorphisms in the clinical impact of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor.
Service de Pharmacologie, Université Pierre et Marie Curie-Paris 6, Assistance Publique-Hôpitaux de Paris, France. tabassome.simon@sat.aphp.fr
T
T
Simon
D000284:Administration, Oral; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D006801:Humans; D011110:Polymorphism, Genetic; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine